secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-12-10T23:59:59+00:00
Accession:  0001493152-25-027072
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA touts $50B immunotherapy market; ateganosine gets Fast Track for NSCLC, Phase 3 starting
--------------------------------------------------------------------------------

- FDA Fast Track Designation for ateganosine in NSCLC patients resistant to immunotherapy and chemotherapy.
- Initiating Phase 3 THIO-104 trial for advanced NSCLC without actionable mutations and CPI-refractory.
- FDA Orphan Drug Designations for glioblastoma, hepatocellular carcinoma, and small cell lung cancer.
- NSCLC market valued at $34.1B, projected to nearly double to $68.8B by 2033.
- Keytruda generated $29.5B revenue in 2024, with ~30% from NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000149315225027072/0001493152-25-027072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000149315225027072/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-027072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer